Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful faithfully but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the past few shares of mine. My first CytoDyn article, “CytoDyn: What In order to Do When It is Too Good In order to Be True?”, set away what follows prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely promotional image in the Uptick Newswire employment interview that I came away with a poor viewpoint of the business.

Irony of irony, my bad opinion of the business enterprise has grown steadily, though the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology and connected intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) along with the very first brand new drug application endorsement ($five million), and even royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and multiple therapies, it’s this individual remedy and a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an active organization with diverse interests albeit focused on leronlimab, several illness sorts, multiple publications and multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the very start of the interest of mine in this organization. Judging by the multiples of thousands of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *